相关实验视频

Updated: May 8, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

布拉斯特:一种全球适用和分子多功能生存模型,用于慢性骨髓单细胞白血病

Ayalew Tefferi¹, Saubia Fathima², Maymona Abdelmagid²

¹Mayo Clinic, Rochester, MN, Minnesota, United States.

|May 7, 2025

概括

一个新的临床风险模型,BLAST,使用爆发,白细胞和贫血来预测慢性骨髓单细胞白血病 (CMML) 的存活率. 结合突变,BLAST-mol模型进一步提高了CMML患者的预后准确性.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

慢性骨髓单细胞白血病 (CMML) 是一种异质骨髓状瘤,预后可变.
准确的风险分层对于指导CMML治疗决策至关重要.
现有的预后模型可能无法完全捕捉分子变化的影响.

研究的目的:

开发和验证一个临床风险分层工具,用于CMML的整体存活率 (OS),名为BLAST.
评估CMML中遗传突变和型的预后附加值.
创建一个结合的临床分子模型 (BLAST-mol) 以提高CMML风险评估.

主要方法:

对457名分子注释CMML患者的回顾性分析.
基于循环中的血清,白细胞计数和贫血的BLAST临床风险评分的发展.
多变量分析以确定独立的预后因素,包括突变 (例如TET2,ASXL1) 和型.
创建和验证联合BLAST-mol模型.

主要成果:

BLAST模型确定了低,中,高风险群体,具有明显的中位 OS (分别为63个,28个和13个月).
BLAST模型的性能 (AUC 0.77/0.85在3/5年) 与现有的CMML-mol和IPSS-M.等模型相比较.
结合分子数据的BLAST-mol模型实现了卓越的性能 (AUC 0.80/0.86在3/5年).
特定突变 (例如,DNMT3A,ASXL1) 和不良型与不利的结果和弹性转变有关.

结论:

BLAST模型为CMML生存预测提供了一个简单,临床适用的工具.
将分子数据集成到BLAST-mol模型中显著提高了预后准确性.
这些模型为CMML风险分层提供了一个全球适用的,分子适应性的方法.

更多相关视频

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...